American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Wrap-Up

Phase 3 ASCENT-04/KEYNOTE-D19 Study: Sacituzumab Govitecan Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab in First-Line, PD-L1–Positive, Advanced TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The ASCENT-04/KEYNOTE-D19 trial highlights sacituzumab govitecan plus pembrolizumab as a promising first-line therapy for patients with programmed death-ligand 1 (PD-L1)-positive, advanced triple-negative breast cancer (TNBC). Read More ›

Phase 3 DeLLphi-304: Primary Analysis of Tarlatamab Versus Chemotherapy as Second-Line Treatment for Patients With SCLC

ASCO 2025 - Small Cell Lung Cancer

The DeLLphi-304 trial shows tarlatamab significantly improves survival with a manageable adverse-event profile over chemotherapy, establishing a new standard of care for patients with small cell lung cancer (SCLC) after platinum-based chemotherapy. Read More ›

A Randomized, Phase 2 Trial Evaluating Atezolizumab Maintenance Therapy Following Chemoradiotherapy in LS-SCLC

ASCO 2025 - Small Cell Lung Cancer

A randomized, phase 2 study found atezolizumab maintenance after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC) did not improve survival outcomes and caused additional toxicities. Read More ›

IMforte Phase 3 Study: Lurbinectedin Plus Atezolizumab Improves Survival in Extensive-Stage Small Cell Lung Cancer

ASCO 2025 - Small Cell Lung Cancer

The IMforte study showed clinically meaningful improvements in progression-free survival and overall survival with lurbinectedin plus atezolizumab compared with atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›

Promising Phase 2 Results for ZG006, a Trispecific T-Cell Engager, in Advanced Small Cell Lung Cancer

ASCO 2025 - Small Cell Lung Cancer

ZG006 demonstrated promising efficacy and a tolerable safety profile in patients with advanced small cell lung cancer, supporting further evaluation in the ongoing phase 2 study. Read More ›

Wrap-Up

MDS/Neoplasms: Time Toxicity for Patients Receiving Oral Versus Parenteral HMAs

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the ASCO 2024 Annual Meeting, researchers presented the differences in time toxicity among patients undergoing myelodysplastic syndromes/neoplasms with oral hypomethylating versus parenteral hypomethylating agents. Read More ›

Wrap-Up

Phase 2 Results From the ASTREON Trial: Preliminary Safety and Efficacy of Oral AZA in Patients With Low-/Intermediate-Risk MDS

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the ASCO 2024 Annual Meeting, researchers presented oral azacitidine’s safety and efficacy results in patients with low-/intermediate-risk myelodysplastic syndromes, as documented in the ASTREON trial. Read More ›

Wrap-Up

Latest Results of a Phase 2 Study of IMM01 Combined With AZA: First-Line Treatment in Adults With HRMDS

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the ASCO 2024 Annual Meeting, researchers summarized the most recent results from the phase 2 study of IMM01 in combination with azacitidine, a first-line treatment for adults with higher-risk myelodysplastic syndromes. Read More ›

Wrap-Up

Efficacy of Luspatercept for the Treatment of Transfusion-Dependent, Erythropoiesis-Stimulating Agent–Naïve Patients With Very Low-, Low-, or Intermediate-Risk MDS in the COMMANDS Trial

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the 2024 ASCO Annual Meeting, researchers’ data from the COMMANDS trial, which evaluated the effectiveness of luspatercept in treating patients with transfusion-dependent, erythropoiesis-stimulating agent–naïve individuals with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›

Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastasis in Triple-Negative or HER2-Positive BC

ASCO 2023 - Breast Cancer

An ongoing phase 2 study is evaluating HER2/HER3-directed  dendritic cell vaccines combined with pembrolizumab in patients with brain metastasis from triple-negative breast cancer or HER2-positive breast cancer. Read More ›

American Society of Clinical Oncology (ASCO)

Page 2 of 31